Erratum: Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer(Bioconjugate Chemistry (2016) 27:3 (737-751) DOI: 10.1021/acs.bioconjchem.5b00687);Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer

Bioconjugate Chemistry

Volumn 27, Issue 3, 2016, Pages 737-751

  Liolios, C ^a   Schafer M ^a   Haberkorn, U ^a,b   Eder, M ^a   Kopka, K ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CHELATION; COPPER COMPOUNDS; PHARMACOKINETICS; TUMORS; UREA; UROLOGY;

BIOCONJUGATES; CELL/B.E; IN-VIVO; PEPTIDE RECEPTOR; PET IMAGING; PROSTATE CANCER CELLS; PROSTATE CANCERS; PROSTATE-SPECIFIC MEMBRANE ANTIGENS; RADIOLIGANDS; RECEPTOR TARGETING;

DISEASES;

ALKYNE; AZIDE; BOMBESIN DERIVATIVE; CHELATING AGENT; ESTER; GALLIUM 68; GASTRIN RELEASING PEPTIDE RECEPTOR; HETERODIMER; MONOMER; PEPTIDOMIMETIC AGENT; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOLIGAND; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING ASSAY; BINDING KINETICS; BIODISTRIBUTION; CATALYSIS; COMPLEX FORMATION; CYCLOADDITION; DRUG DISTRIBUTION; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC50; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PANCREAS CELL; PHARMACOPHORE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RADIOACTIVITY; SPLEEN FUNCTION; ANIMAL; DIAGNOSTIC IMAGING; METABOLISM; PHARMACOKINETICS; PROSTATE TUMOR; RADIOASSAY; STANDARDS;

ANIMALS; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; PHARMACOKINETICS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOLIGAND ASSAY;

EID: 84962321744     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.6b00311     Document Type: Erratum

References (52)

1. Yan, Y. and Chen, X. (2011) Peptide heterodimers for molecular imaging Amino Acids 41, 1081-1092 10.1007/s00726-010-0546-y
2. Schroeder, R. P. J., van Weerden, W. M., Bangma, C., Krenning, E. P., and de Jong, M. (2009) Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues Methods 48, 200-4 10.1016/j.ymeth.2009.04.002
3. 68Ga-labeled peptides in tumor imaging J. Nucl. Med. 46, 172S-8S
4. Lee, S., Xie, J., and Chen, X. (2010) Peptide-based probes for targeted molecular imaging Biochemistry 49, 1364-76 10.1021/bi901135x
5. Okarvi, S. M. (2004) Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases Med. Res. Rev. 24, 357-97 10.1002/med.20002
6. Reubi, J. C. and Maecke, H. R. (2008) Peptide-based probes for cancer imaging J. Nucl. Med. 49, 1735-8 10.2967/jnumed.108.053041
7. Chen, K. and Conti, P. S. (2010) Target-specific delivery of peptide-based probes for PET imaging Adv. Drug Delivery Rev. 62, 1005-22 10.1016/j.addr.2010.09.004
8. Fani, M., Maecke, H. R., and Okarvi, S. M. (2012) Radiolabeled peptides: Valuable tools for the detection and treatment of cancer Theranostics 2, 481-501 10.7150/thno.4024
9. Dijkgraaf, I., Kruijtzer, J. A. W., Liu, S., Soede, A. C., Oyen, W. J. G., Corstens, F. H. M., Liskamp, R. M. J., and Boerman, O. C. (2007) Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides Eur. J. Nucl. Med. Mol. Imaging 34, 267-73 10.1007/s00259-006-0180-9
10. Kubas, H., Schäfer, M., Bauder-Wüst, U., Eder, M., Oltmanns, D., Haberkorn, U., Mier, W., and Eisenhut, M. (2010) Multivalent cyclic RGD ligands: Influence of linker lengths on receptor binding Nucl. Med. Biol. 37, 885-891 10.1016/j.nucmedbio.2010.06.005
11. Handl, H. L., Vagner, J., Han, H., Mash, E., Hruby, V. J., and Gillies, R. J. (2004) Hitting multiple targets with multimeric ligands Expert Opin. Ther. Targets 8, 565-586 10.1517/14728222.8.6.565
12. Sancey, L., Garanger, E., Foillard, S., Schoehn, G., and Hurbin, A. et al. 2009, Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide Mol. Ther. 17, 837-43 10.1038/mt.2009.29
13. Yan, Y., Chen, K., Yang, M., Sun, X., Liu, S., and Chen, X. (2011) A new 18 F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging Amino Acids 41, 439-447 10.1007/s00726-010-0762-5
14. Berque-Bestel, I., Lezoualc'h, F., and Jockers, R. (2008) Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers Curr. Drug Discovery Technol. 5, 312-8 10.2174/157016308786733591
15. Shallal, H. M., Minn, I., Banerjee, S. R., Lisok, A., Mease, R. C., and Pomper, M. G. (2014) Heterobivalent agents targeting PSMA and integrin-αvβ3 Bioconjugate Chem. 25, 393-405 10.1021/bc4005377
16. Shrivastava, A., Wang, S.-H., Raju, N., Gierach, I., Ding, H., and Tweedle, M. F. (2013) Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells Bioorg. Med. Chem. Lett. 23, 687-92 10.1016/j.bmcl.2012.11.110
17. 64Cu-labeled RGD-bombesin heterodimer J. Nucl. Med. 50, 1168-77 10.2967/jnumed.108.061739
18. de Visser, M., van Weerden, W. M., de Ridder, C. M. a, Reneman, S., Melis, M., Krenning, E. P., and de Jong, M. (2007) Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts J. Nucl. Med. 48, 88-93
19. Sancho, V., Di Florio, A., Moody, T. W., and Jensen, R. T. (2011) Bombesin receptor-mediated imaging and cytotoxicity: Review and current status Curr. Drug Delivery 8, 79-134 10.2174/156720111793663624
20. Cornelio, D. B., Roesler, R., and Schwartsmann, G. (2007) Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy Ann. Oncol. 18, 1457-66 10.1093/annonc/mdm058
21. Rybalov, M., Ananias, H. J. K., Hoving, H. D., van der Poel, H. G., Rosati, S., and de Jong, I. J. (2014) PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy Int. J. Mol. Sci. 15, 6046-61 10.3390/ijms15046046
22. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging Eur. J. Nucl. Med. Mol. Imaging 36, 1483-94 10.1007/s00259-009-1123-z
23. 3-Glu-RGD-BBN J. Med. Chem. 52, 425-32 10.1021/jm801285t
24. 2: A heterodimeric targeting vector for positron emission tomography imaging of prostate cancer Nucl. Med. Biol. 39, 377-87 10.1016/j.nucmedbio.2011.10.004
25. 64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors Nucl. Med. Biol. 41, 133-9 10.1016/j.nucmedbio.2013.11.006
26. 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer Bioconjugate Chem. 20, 1016-25 10.1021/bc9000245
27. Yao, V., Berkman, C. E., Choi, J. K., O'Keefe, D. S., and Bacich, D. J. (2009) Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid Prostate 70, 305-16 10.1002/pros.21065
28. Wang, X., Ma, D., Olson, W. C., and Heston, W. D. W. (2011) In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen Mol. Cancer Ther. 10, 1728-39 10.1158/1535-7163.MCT-11-0191
29. Mannweiler, S., Amersdorfer, P., Trajanoski, S., Terrett, J. a, King, D., and Mehes, G. (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis Pathol. Oncol. Res. 15, 167-72 10.1007/s12253-008-9104-2
30. Eder, M., Schäfer, M., Bauder-Wüst, U., Haberkorn, U., Eisenhut, M., and Kopka, K. (2014) Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer Prostate 74, 659-68 10.1002/pros.22784
31. 68Ga-labeled bombesin(6-14) analog J. Nucl. Med. 46, 691-9
32. 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line EJNMMI Res. 1, 34 10.1186/2191-219X-1-34
33. Strauss, L. G., Koczan, D., Seiz, M., Tuettenberg, J., Schmieder, K., Pan, L., Cheng, C., and Dimitrakopoulou-Strauss, A. (2012) Correlation of the Ga-68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays Mol. Imaging Biol. 14, 376-83 10.1007/s11307-011-0508-0
34. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging Bioconjugate Chem. 23, 688-97 10.1021/bc200279b
35. 68Ga-PET imaging of prostate cancer EJNMMI Res. 2, 23 10.1186/2191-219X-2-23
36. 213Bi]J591) for Radioimmunotherapy of Prostate Cancer Cancer Res. 60, 6095-6100
37. 68Ga-labeled bombesin(6-14) analog J. Nucl. Med. 46, 691-699
38. 99mTc-labelled bombesin-like peptides for optimizing pharmacokinetics in prostate tumor targeting Int. J. Pharm. 430, 1-17 10.1016/j.ijpharm.2012.02.049
39. 3-conjugates in important organs J. Nucl. Med. 54, 1327-30 10.2967/jnumed.112.114512
40. 99mTc, (111)In, and (125)I J. Med. Chem. 54, 3817-26 10.1021/jm200065e
41. Osborne, J. R., Akhtar, N. H., Vallabhajosula, S., Anand, A., Deh, K., and Tagawa, S. T. (2013) Prostate-specific membrane antigen-based imaging Urol. Oncol. 31, 144-54 10.1016/j.urolonc.2012.04.016
42. Melis, M., Krenning, E. P., Bernard, B. F., de Visser, M., Rolleman, E., and de Jong, M. (2007) Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: Species and gender differences Nucl. Med. Biol. 34, 633-41 10.1016/j.nucmedbio.2007.05.002
43. Melis, M., Krenning, E. P., Bernard, B. F., Barone, R., Visser, T. J., and de Jong, M. (2005) Localisation and mechanism of renal retention of radiolabelled somatostatin analogues Eur. J. Nucl. Med. Mol. Imaging 32, 1136-43 10.1007/s00259-005-1793-0
44. Mahmood, I. (2007) Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development Adv. Drug Delivery Rev. 59, 1177-92 10.1016/j.addr.2007.05.015
45. 64Cu-Labeled Peptides for PET Imaging J. Nucl. Med. 55, 1719-1725 10.2967/jnumed.114.141242
46. 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26 Nucl. Med. Biol. 42, 446-454 10.1016/j.nucmedbio.2014.12.009
47. Mansi, R., Wang, X., Forrer, F., Waser, B., Cescato, R., Graham, K., Borkowski, S., Reubi, J. C., and Maecke, H. R. (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours Eur. J. Nucl. Med. Mol. Imaging 38, 97-107 10.1007/s00259-010-1596-9
48. 68Ga-PSMA PET in Patients with Biochemically Recurrent Prostate Cancer J. Nucl. Med. 10.2967/jnumed.115.168393
49. 68Ga radioisotope generator system for production of 68Ga in dilute HCl Int. J. Appl. Radiat. Isot. 32, 31-36 10.1016/0020-708X(81)90174-5
50. 68Ga-labeled small recombinant antibodies Eur. J. Nucl. Med. Mol. Imaging 35, 1878-86 10.1007/s00259-008-0816-z
51. Zoller, M., Schuhmacher, J., Reed, J., Maier-Borst, W., Matzku, S., Zöller, M., Schuhmacher, J., Reed, J., Maier-Borst, W., and Matzku, S. (1992) Establishment and characterization of monoclonal antibodies against an octahedral gallium chelate suitable for immunoscintigraphy with PET J. Nucl. Med. 33, 1366-1372
52. Akeson, M., Sainz, E., Mantey, S. a, Jensen, R. T., and Battey, J. F. (1997) Identification of four amino acids in the gastrin-releasing peptide receptor that are required for high affinity agonist binding J. Biol. Chem. 272, 17405-17409 10.1074/jbc.272.28.17405